Boston Family Office LLC Buys 213 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Boston Family Office LLC grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,763 shares of the company’s stock after buying an additional 213 shares during the period. Boston Family Office LLC’s holdings in CRISPR Therapeutics were worth $459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Global Trust Asset Management LLC increased its position in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC increased its position in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC increased its position in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in CRISPR Therapeutics in the second quarter worth $35,000. Finally, Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics in the third quarter worth $43,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock worth $1,917,679 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10. The company has a market capitalization of $4.30 billion, a PE ratio of -17.81 and a beta of 1.67. The company has a 50-day simple moving average of $47.98 and a two-hundred day simple moving average of $51.73.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the company posted ($1.41) earnings per share. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CRSP shares. Barclays cut their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Truist Financial cut their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.